secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0000950103-25-010408
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Precigen enters into commercial supply agreement with Catalent for PAPIZEMOS manufacturing
--------------------------------------------------------------------------------

- Agreement dated August 13, 2025 with Catalent Maryland for fill/finish services for gene therapy PAPIZEMOS (PRGN-2012).
- Precigen grants Catalent exclusive rights for external commercial fill/finish manufacturing of the product in the Territory.
- Initial term of three years, automatically renews annually unless 12-month termination notice given.
- Precigen commits to minimum batch purchases per contract year as specified in the Plan Document.
- Pricing subject to annual adjustment based on labor, utilities, and overhead costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010325010408/0000950103-25-010408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010325010408/dp233151_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-25-010408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer